{
  "source": "PA-Med-Nec-Duvyzat.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2346-1\nProgram Prior Authorization/Medical Necessity\nMedication Duvyzat™ (givinostat) oral suspension\nP&T Approval Date 7/2024\nEffective Date 10/1/2024\n1. Background:\nDuvyzat (givinostat) is a histone deacetylase inhibitor indicated for the treatment of Duchenne\nmuscular dystrophy (DMD) in patients 6 years of age and older.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Duvyzat will be approved based upon all of the following criteria:\na. Diagnosis of Duchenne muscular dystrophy (DMD)\n-AND-\nb. Diagnosis confirmed by the presence of a mutation in the DMD gene\n-AND-\nc. Patient is 6 years of age or older\n-AND-\nd. Submission of medical records (e.g., chart notes) confirming that the patient is\nambulatory without needing an assistive device (e.g., without side-by-side assist,\ncane, walker, wheelchair, etc.)\n-AND-\ne. Patient has been or will be established on a stable corticosteroid regimen\n-AND-\nf. Prescribed by, or in consultation with, a pediatric neuromuscular specialist with\nexpertise in the treatment of DMD\n-AND-\ng. Patient has not received gene therapy for DMD [e.g., Elevidys (delandistrogene\nmoxparvovec-rokl)]\n-AND-\n© 2024 UnitedHealthcare Services, Inc.\n1\nh. Patient will not receive Duvyzat in combination with exon-skipping therapies for\nDMD [e.g., Amondys (casimersen), Exondys 51 (eteplirsen), Viltepso (viltolarsen),\nVyondys 53 (golodirsen)]\nAuthorization will be issued for 12 months.\nB. Reauthorization\n1. Duvyzat will be approved based on all the following criterion:\na. Physician attestation that patient would benefit from continued administration.\n-AND-\nb. Submission of medical records (e.g., chart notes) confirming that the patient is\nambulatory without needing an assistive device (e.g., without side-by-side assist,\ncane, walker, wheelchair, etc.)\n-AND-\nc. Patient continues to receive concomitant corticosteroid regimen\n-AND-\nd. Prescribed by, or in consultation with, a pediatric ne",
    "., without side-by-side assist,\ncane, walker, wheelchair, etc.)\n-AND-\nc. Patient continues to receive concomitant corticosteroid regimen\n-AND-\nd. Prescribed by, or in consultation with, a pediatric neuromuscular specialist with\nexpertise in the treatment of DMD\n-AND-\ne. Patient has not received gene therapy for DMD [e.g., Elevidys (delandistrogene\nmoxparvovec-rokl)]\n-AND-\nf. Patient will not receive Duvyzat in combination with exon-skipping therapies for\nDMD [e.g., Amondys (casimersen), Exondys 51 (eteplirsen), Viltepso (viltolarsen),\nVyondys 53 (golodirsen)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n© 2024 UnitedHealthcare Services, Inc.\n2\n4. Reference:\n1. Duvyzat [package insert]. Concord, MA: ITF Therapeutics, LLC; March 2024.\n2. Mercuri E, Vilchez JJ, Boespflug-Tanguy O, et al. Safety and efficacy of givinostat in boys with\nDuchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-\ncontrolled, phase 3 trial [published correction appears in Lancet Neurol. 2024 Jun;23(6):e10].\nLancet Neurol. 2024;23(4):393-403.\n3. Gloss D, Moxley III R, Ashwal S, et. al. Practice guideline update summary: Corticosteroid\ntreatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee\nof the American Academy of Neurology. Neurology 2016; 86;465-472.\nProgram Prior Authorization/Medical Necessity - Duvyzat (givinostat)\nChange Control\n7/2024 New program.\n© 2024 UnitedHealthcare Serv",
    "e\nof the American Academy of Neurology. Neurology 2016; 86;465-472.\nProgram Prior Authorization/Medical Necessity - Duvyzat (givinostat)\nChange Control\n7/2024 New program.\n© 2024 UnitedHealthcare Services, Inc.\n3"
  ]
}